Emerging Therapeutics for Ocular Surface Disease

Topical Tacrolimus 0.03% for Maintenance Therapy in Steroid-Dependent, Recurrent Phlyctenular Keratoconjunctivitis

(2018) Chang Ho Yoon et al.   CORNEA

Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile

(2018) Lena Ripa et al.   JOURNAL OF MEDICINAL CHEMISTRY

Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness

(2018) Eugene McLaurin et al.   OPTOMETRY AND VISION SCIENCE

A Rapid Extraction Method to Quantify Drug Uptake in Contact Lenses

(2018) Chau-Minh Phan et al.   Translational Vision Science & Technology

Comparison of the efficacy of 0.03% tacrolimus eye drops diluted in olive oil and linseed oil for the treatment of keratoconjunctivitis sicca in dogs

(2018) Luís Felipe da Costa Zulim et al.   ARQUIVOS BRASILEIROS DE OFTALMOLOGIA

DS-70, a novel and potent α4 integrin antagonist, is an effective treatment for experimental allergic conjunctivitis in guinea pigs

(2018) Samantha Deianira Dattoli et al.   BRITISH JOURNAL OF PHARMACOLOGY

Topical cis-urocanic acid prevents ocular surface irritation in both IgE -independent and -mediated rat model

(2017) Hanna-Mari Jauhonen et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Therapeutic Effect of 0.1% Tacrolimus Eye Drops in the Tarsal Form of Vernal Keratoconjunctivitis

(2017) Qi Wan et al.   OPHTHALMIC RESEARCH

Steroid-Sparing Effect of 0.1% Tacrolimus Eye Drop for Treatment of Shield Ulcer and Corneal Epitheliopathy in Refractory Allergic Ocular Diseases

(2017) Dai Miyazaki et al.   OPHTHALMOLOGY

Vernal keratoconjunctivitis treated with omalizumab: A case series

(2017) Francesca Occasi et al.   PEDIATRIC ALLERGY AND IMMUNOLOGY

Increased cis-to-trans urocanic acid ratio in the skin of chronic spontaneous urticaria patients

(2017) Duy Le Pham et al.   Scientific Reports

Biomimetic contact lenses eluting olopatadine for allergic conjunctivitis

(2016) Clara González-Chomón et al.   Acta Biomaterialia

Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses

(2016) Samuel Gause et al.   ADVANCES IN COLLOID AND INTERFACE SCIENCE

Emerging therapeutics for ocular surface disease

(2016) Brett P. Bielory et al.   Current Opinion in Allergy and Clinical Immunology

TRPV1 Antagonist Suppresses Allergic Conjunctivitis in a Murine Model

(2016) Ji Young Kwon et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

Omalizumab Treatment of Vernal Keratoconjunctivitis

(2016) Enrico Heffler et al.   JAMA Ophthalmology

A randomized phase I clinical study of cis-urocanic acid eye drops in healthy adult subjects

(2015) Hanna-Mari Jauhonen et al.   ACTA OPHTHALMOLOGICA

Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model

(2015) Eugene McLaurin et al.   CORNEA

Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials

(2014) Eugene B. McLaurin et al.   ADVANCES IN THERAPY

Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis

(2014) Xiao Chloe Wan et al.   Expert Opinion on Drug Metabolism & Toxicology

An algorithm for the management of allergic conjunctivitis

(2013) Leonard Bielory et al.   ALLERGY AND ASTHMA PROCEEDINGS

Comparative Evaluation of Olopatadine 0.01% Combined Fluorometholone 0.1% Treatment Versus Olopatadine 0.01% Combined Ketorolac 0.4% Treatment in Patients with Acute Seasonal Allergic Conjunctivitis

(2013) Tuba Celik et al.   CURRENT EYE RESEARCH

Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab

(2013) Timothy A. de Klerk et al.   JOURNAL OF AAPOS

Effectiveness of Nonpharmacologic Treatments for Acute Seasonal Allergic Conjunctivitis

(2013) Paramdeep S. Bilkhu et al.   OPHTHALMOLOGY

Loteprednol Etabonate Suspension 0.2% Administered QID Compared With Olopatadine Solution 0.1% Administered BID in the Treatment of Seasonal Allergic Conjunctivitis: A Multicenter, Randomized, Investigator-Masked, Parallel Group Study in Chinese Patients

(2012) Lan Gong et al.   CLINICAL THERAPEUTICS

Delivery of Ketotifen Fumarate by Commercial Contact Lens Materials

(2012) Anthony Soluri et al.   OPTOMETRY AND VISION SCIENCE

Omalizumab. An option in vernal keratoconjunctivitis?

(2011) J. Sánchez et al.   ALLERGOLOGIA ET IMMUNOPATHOLOGIA

Beneficial Pharmacological Effects of Selective Glucocorticoid Receptor Agonist in External Eye Diseases

(2011) Masatomo Kato et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

The epidemiology of ocular and nasal allergy in the United States, 1988-1994

(2010) Kavita Singh et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Emerging drugs for conjunctivitis

(2009) Catherine Origlieri et al.   EXPERT OPINION ON EMERGING DRUGS

Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial

(2008) Mehmet Borazan et al.   ACTA OPHTHALMOLOGICA

Contact Lenses and Associated Anterior Segment Disorders: Dry Eye Disease, Blepharitis, and Allergy

(2008) Michael A. Lemp et al.   IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA